Reversion of steatosis by SREBP-1c antisense oligonucleotide did not improve hepatic insulin action in diet-induced obesity mice

Hormone and Metabolic Research

Volumn 44, Issue 12, 2012, Pages 885-890

  Vitto, M F ^a   Luz, G ^a   Luciano, T F ^a   Marques, S O ^a   Souza, D R ^a   Pinho, R A ^a   Lira, F S ^a   Cintra, D E ^b   De Souza, C T ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

inflammation; insulin resistance; SREBP 1c; steatosis

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GLUCOSE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; JANUS KINASE; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET; EPIDIDYMIS FAT; FATTY LIVER; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; DIET, HIGH-FAT; FATTY LIVER; INJECTIONS, INTRAPERITONEAL; INSULIN; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPID METABOLISM; LIPOTROPIC AGENTS; LIVER; MALE; MICE; OBESITY; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RANDOM ALLOCATION; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMALIA; MUS;

EID: 84869494161     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1321819     Document Type: Article

References (32)

1. Lazo M., Clark J. M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis: 2008; 28 339 350
2. Ahmed M. H., Byrne C. D. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today: 2007; 12 740 747
3. Frederico M. J., Vitto M. F., Cesconetto P. A., Engelmann J., De Souza D. R., Luz G., Pinho R. A., Ropelle E. R., Cintra D. E., De Souza C. T. Short-term inhibition of SREBP-1c expression reverses diet-induced non-alcoholic fatty liver disease in mice. Scand J Gastroenterol: 2011; 46 1381 1388
4. Bugianesi E., Moscatiello S., Ciaravella M. F., Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des: 2010; 16 1941 1951
5. Cheatham B., Kahn C. R. Insulin action and the insulin signaling network. Endocr Rev: 1995; 16 117 142
6. Youngren J. F. Regulation of insulin receptor function. Cell Mol Life Sci: 2007; 64 873 891
7. MacDonald P. E., Joseph J. W., Yau D., Diao J., Asghar Z., Dai F., Oudit G. Y., Patel M. M., Backx P. H., Wheeler M. B. Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinositide 3-kinase. Endocrinology: 2004; 145 4078 483
8. Guillermet-Guibert J., Bjorklof K., Salpekar A., Gonella C., Ramadani F., Bilancio A., Meek S., Smith A. J., Okkenhaug K., Vanhaesebroeck B. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA: 2008; 105 8292 8297
9. Marchesini G., Moscatiello S., Di Domizio S., Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab: 2008; 93 74 80
10. Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest: 1995; 95 2409 2415
11. Cai D., Frantz J. D., Tawa N. E. Jr, Melendez P. A., Oh B. C., Lidov H. G., Hasselgren P. O., Frontera W. R., Lee J., Glass D. J., Shoelson S. E. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell: 2004; 119 285 298
12. Ragheb R., Medhat A. M., Shanab G. M., Seoudi D. M., Fantus I. G. Links between enhanced fatty acid flux, protein kinase C and NFkappaB activation, and apoB-lipoprotein production in the fructose-fed hamster model of insulin resistance. Biochem Biophys Res Commun: 2008; 370 134 139
13. Bonora E., Moghetti P., Zancanaro C., Cigolini M., Querena M., Cacciatori V., Corgnati A., Muggeo M. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab: 1989; 68 374 378
14. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem: 1976; 72 248 254
15. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature: 1970; 227 680 685
16. De Souza C. T., Araujo E. P., Bordin S., Ashimine R., Zollner R. L., Boschero A. C., Saad M. J., Velloso L. A. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology: 2005; 146 4192 4199
17. Barbuio R., Milanski M., Bertolo M. B., Saad M. J., Velloso L. A. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol: 2007; 194 539 550
18. Marchesini G., Bianchi G. Nonalcoholic fatty liver disease: Disease and comorbidity effects on quality of life. Nat Rev Gastroenterol Hepatol: 2009; 6 504 506
19. Cheung O., Sanyal A. J. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol: 2010; 26 202 208
20. Samuel V. T., Liu Z. X., Qu X., Elder B. D., Bilz S., Befroy D., Romanelli A. J., Shulman G. I. Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease. J Biol Chem: 2004; 279 32345 32353
21. Lam T. K., Van de Werve G., Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol: 2003; 284 281 290
22. He X. M., Yang Q. H., Li P. F., Chen Z., Feng G. F., Wang W. J., Liu H. T., Zhang Y. P., Ji G. Y. Effect of soothing liver and invigorating spleen recipes on SREBP-1c mRNA and protein expression in hepatic tissues of rats with non-alcoholic fatty liver disease. Zhong Yao Cai: 2011; 34 931 937
23. Moon Y. A., Liang G., Xie X., Frank-Kamenetsky M., Fitzgerald K., Koteliansky V., Brown M. S., Goldstein J. L., Horton J. D. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab: 2012; 15 240 246
24. Nakatani Y., Kaneto H., Kawamori D., Hatazaki M., Miyatsuka T., Matsuoka T. A., Kajimoto Y., Matsuhisa M., Yamasaki Y., Hori M. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem: 2004; 279 45803 45809
25. Hotamisligil G. S., Shargill N. S., Spiegelman B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science: 1993; 259 87 91
26. Samuel V. T., Liu Z. X., Wang A., Beddow S. A., Geisler J. G., Kahn M., Zhang X. M., Monia B. P., Bhanot S., Shulman G. I. Inhibition of protein kinase C epsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest: 2007; 117 739 745
27. Hirosumi J., Tuncman G., Chang L., Gorgun C. Z., Uysal K. T., Maeda K., Karin M., Hotamisligil G. S. A central role for JNK in obesity and insulin resistance. Nature: 2002; 420 333 336
28. Arkan M. C., Hevener A. L., Greten F. R., Maeda S., Li Z. W., Long J. M., Wynshaw-Boris A., Poli G., Olefsky J., Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med: 2005; 11 191 198
29. Jiang S., Messina J. L. Role of inhibitory κB kinase and c-Jun NH2-terminal kinase in the development of hepatic insulin resistance in critical illness diabetes. Am J Physiol: 2011; 301 454 463
30. Turner J. J., Foxwell K. M., Kanji R., Brenner C., Wood S., Foxwell B. M., Feldmann M. Investigation of nuclear factor-κB inhibitors and interleukin-10 as regulators of inflammatory signalling in human adipocytes. Clin Exp Immunol: 2010; 162 487 493
31. Lira F. S., Rosa J. C., Pimentel G. D., Seelaender M., Damaso A. R., Oyama L. M., do Nascimento C. O. Both adiponectin and interleukin-10 inhibit LPS-induced activation of the NF-κB pathway in 3T3-L1 adipocytes. Cytokine: 2012; 57 98 106
32. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W. Z., Strowig T., Thaiss C. A., Kau A. L., Eisenbarth S. C., Jurczak M. J., Camporez J. P., Shulman G. I., Gordon J. I., Hoffman H. M., Flavell R. A. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature: 2012; 482 179 185